CN1890258A - 合成培哚普利及其可药用盐的方法 - Google Patents
合成培哚普利及其可药用盐的方法 Download PDFInfo
- Publication number
- CN1890258A CN1890258A CNA2004800363546A CN200480036354A CN1890258A CN 1890258 A CN1890258 A CN 1890258A CN A2004800363546 A CNA2004800363546 A CN A2004800363546A CN 200480036354 A CN200480036354 A CN 200480036354A CN 1890258 A CN1890258 A CN 1890258A
- Authority
- CN
- China
- Prior art keywords
- urea
- tetramethyl
- dihydro
- oxo
- benzotriazole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 16
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 title claims abstract description 15
- 229960002582 perindopril Drugs 0.000 title claims abstract description 15
- 150000003839 salts Chemical class 0.000 title claims abstract description 10
- 230000015572 biosynthetic process Effects 0.000 title claims abstract description 7
- 238000003786 synthesis reaction Methods 0.000 title claims abstract description 7
- -1 benzyl ester Chemical class 0.000 claims description 29
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 claims description 22
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 13
- 239000004202 carbamide Substances 0.000 claims description 13
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 claims description 13
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 8
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 238000009903 catalytic hydrogenation reaction Methods 0.000 claims description 5
- 239000007822 coupling agent Substances 0.000 claims description 5
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 claims description 4
- CFMZSMGAMPBRBE-UHFFFAOYSA-N 2-hydroxyisoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(O)C(=O)C2=C1 CFMZSMGAMPBRBE-UHFFFAOYSA-N 0.000 claims description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 4
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 4
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 4
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 claims description 4
- 239000012964 benzotriazole Substances 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- HOGDNTQCSIKEEV-UHFFFAOYSA-N n'-hydroxybutanediamide Chemical compound NC(=O)CCC(=O)NO HOGDNTQCSIKEEV-UHFFFAOYSA-N 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 claims description 4
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 claims description 4
- 229910052698 phosphorus Inorganic materials 0.000 claims description 4
- 239000011574 phosphorus Substances 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical group CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 claims description 4
- DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 claims description 4
- 239000002585 base Substances 0.000 claims description 3
- 238000005984 hydrogenation reaction Methods 0.000 claims description 3
- SYOANZBNGDEJFH-UHFFFAOYSA-N 2,5-dihydro-1h-triazole Chemical compound C1NNN=C1 SYOANZBNGDEJFH-UHFFFAOYSA-N 0.000 claims description 2
- SMYDMMALUBNVRU-UHFFFAOYSA-N CN(C)[P] Chemical compound CN(C)[P] SMYDMMALUBNVRU-UHFFFAOYSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims description 2
- 239000003513 alkali Substances 0.000 claims description 2
- HOPRXXXSABQWAV-UHFFFAOYSA-N anhydrous collidine Natural products CC1=CC=NC(C)=C1C HOPRXXXSABQWAV-UHFFFAOYSA-N 0.000 claims description 2
- 150000001642 boronic acid derivatives Chemical class 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
- 239000011707 mineral Substances 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims description 2
- 229910052763 palladium Inorganic materials 0.000 claims description 2
- 239000001294 propane Substances 0.000 claims description 2
- 230000002194 synthesizing effect Effects 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- UAEPNZWRGJTJPN-UHFFFAOYSA-N methylcyclohexane Chemical compound CC1CCCCC1 UAEPNZWRGJTJPN-UHFFFAOYSA-N 0.000 description 6
- 238000003756 stirring Methods 0.000 description 4
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- GYNNXHKOJHMOHS-UHFFFAOYSA-N methyl-cycloheptane Natural products CC1CCCCCC1 GYNNXHKOJHMOHS-UHFFFAOYSA-N 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- IPVQLZZIHOAWMC-KYWGXEQASA-N (2s)-1-[2-[[(2s)-1-ethoxy-1-oxopentan-2-yl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid Chemical compound C1CCCC2C[C@@H](C(O)=O)N(C(=O)C(C)N[C@@H](CCC)C(=O)OCC)C21 IPVQLZZIHOAWMC-KYWGXEQASA-N 0.000 description 1
- 102000005862 Angiotensin II Human genes 0.000 description 1
- 101800000734 Angiotensin-1 Proteins 0.000 description 1
- 102400000344 Angiotensin-1 Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 208000037849 arterial hypertension Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- ARGCRCXTJMQKNA-KKUMJFAQSA-N benzyl (2s,3as,7as)-2,3,3a,4,5,6,7,7a-octahydro-1h-indole-2-carboxylate Chemical compound O=C([C@H]1N[C@H]2CCCC[C@H]2C1)OCC1=CC=CC=C1 ARGCRCXTJMQKNA-KKUMJFAQSA-N 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 150000001261 hydroxy acids Chemical group 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 108010021724 tonin Proteins 0.000 description 1
- 229950004288 tosilate Drugs 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Peptides Or Proteins (AREA)
- Indole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
本发明涉及工业合成式(I)培哚普利及其可药用盐的方法。
Description
本发明涉及合成式(I)培哚普利及其可药用盐的方法:
培哚普利及其可药用盐,更尤其是其叔丁胺盐,具有有价值的药理性质。它们的主要性质是抑制血管紧张素I转化酶(或激肽酶II),这一方面阻止十肽血管紧张素I转化为八肽血管紧张素II(血管收缩剂),另一方面阻止缓激肽(血管扩张剂)降解为无活性的肽。这两种作用有利于培哚普利在心血管疾病、更尤其是在高动脉压和心力衰竭中的有益作用。
培哚普利、其制备及其在治疗中的用途已经在欧洲专利说明书EP 0049 658中有描述。
鉴于该化合物的药用价值,重要的是能够通过有效的合成方法获得该化合物,所述的方法可容易地转化为工业规模,以良好的产率且尤其是极好的纯度生成培哚普利。专利说明书EP 0 308 341描述了培哚普利的工业合成,该方法通过将(2S,3aS,7aS)-八氢吲哚-2-甲酸苄基酯与N-[(S)-1-羧基丁基]-(S)-丙氨酸乙酯在二环己基碳二亚胺存在下偶联、然后通过催化氢化使杂环的羧酸基团去保护来进行。该方法的优点是使用二环己基碳二亚胺。
申请人已经开发了一种使用其它偶联剂来合成培哚普利的方法。
更具体而言,本发明涉及合成培哚普利的方法,该方法的特征在于:使式(IIa)或(IIb)的苄基酯或者式(IIa)或(IIb)的酯与无机酸或有机酸的加成盐
与式(III)化合物
在偶联剂的存在下反应,所述的偶联剂选自下述试剂和试剂对:
(1,3-二甲基氨基丙基)-3-乙基-碳二亚胺盐酸盐,
(1,3-二甲基氨基丙基)-3-乙基-碳二亚胺盐酸盐/1-羟基苯并三唑,
(1,3-二甲基氨基丙基)-3-乙基-碳二亚胺盐酸盐/1-羟基-7-氮杂苯并三唑,
(1,3-二甲基氨基丙基)-3-乙基-碳二亚胺盐酸盐/N-羟基琥珀酰亚胺,
(1,3-二甲基氨基丙基)-3-乙基-碳二亚胺盐酸盐/3-羟基-3,4-二氢-4-氧代-1,2,3-苯并三嗪,
(1,3-二甲基氨基丙基)-3-乙基-碳二亚胺盐酸盐/N-羟基苯邻二甲酰亚胺,
二环己基碳二亚胺/1-羟基-7-氮杂苯并三唑,
二环己基碳二亚胺/N-羟基琥珀酰亚胺,
二环己基碳二亚胺/3-羟基-3,4-二氢-4-氧代-1,2,3-苯并三嗪,
二环己基碳二亚胺/N-羟基苯邻二甲酰亚胺,
O-(苯并三唑-1-基)-1,1,3,3-四甲基脲六氟磷酸盐,
O-(7-氮杂苯并三唑-1-基)-1,1,3,3-四甲基脲六氟磷酸盐,
O-(苯并三唑-1-基)-1,1,3,3-四甲基脲四氟硼酸盐,
苯并三唑-1-基-氧基三吡咯烷子基磷六氟磷酸盐,
苯并三唑-1-基-氧基-三(二甲基氨基)磷六氟磷酸盐,
O-(苯并三唑-1-基)-1,1,3,3-双(四亚甲基)脲六氟磷酸盐,
O-(苯并三唑-1-基)-1,1,3,3-双(五亚甲基)脲六氟磷酸盐,
氯代-三吡咯烷子基磷六氟磷酸盐,
氯代-1,1,3,3-双(四亚甲基)甲脒(formamidinium)六氟磷酸盐,
氯代-1,1,3,3-双(五亚甲基)甲脒六氟磷酸盐,
N-乙氧羰基-2-乙氧基-1,2-二氢喹啉,
O-[(乙氧羰基)-氰基亚甲基氨基]-1,1,3,3-四甲基脲四氟硼酸盐,
O-(3,4-二氢-4-氧代-1,2,3-苯并三嗪-3-基)-1,1,3,3-四甲基脲四氟硼酸盐,
O-(3,4-二氢-4-氧代-1,2,3-苯并三嗪-3-基)-1,1,3,3-四甲基脲四氟硼酸盐/1-羟基苯并三唑,
O-(3,4-二氢-4-氧代-1,2,3-苯并三嗪-3-基)-1,1,3,3-四甲基脲四氟硼酸盐/N-甲基吗啉,
O-(3,4-二氢-4-氧代-1,2,3-苯并三嗪-3-基)-1,1,3,3-四甲基脲四氟硼酸盐/三甲基吡啶,
O-(1,2-二氢-2-氧代-1-吡啶基)-1,1,3,3-四甲基脲四氟硼酸盐,
O-(1,2-二氢-2-氧代-1-吡啶基)-1,1,3,3-四甲基脲四氟硼酸盐/1-羟基-苯并三唑,
O-(1,2-二氢-2-氧代-1-吡啶基)-1,1,3,3-双(四亚甲基)脲六氟磷酸盐,
O-(1,2-二氢-2-氧代-1-吡啶基)-1,1,3,3-双(四亚甲基)脲六氟磷酸盐/1-羟基-苯并三唑,
O-(N-琥珀酰亚氨基)-1,1,3,3-四甲基脲四氟硼酸盐,
O-(N-琥珀酰亚氨基)-1,1,3,3-双(四亚甲基)脲四氟硼酸盐,
O-(N-琥珀酰亚氢基)-1,1,3,3-双(四亚甲基)脲四氟硼酸盐/1-羟基苯并三唑,
O-(5-降冰片烯-2,3-二甲酰亚氨基(dicarboximido))-1,1,3,3-四甲基脲四氟硼酸盐,
丙烷磷酸酐,
N-羟基-5-降冰片烯-2,3-二甲酰亚胺,和
N-羟基-1,2-二氢-2-氧代-吡啶,
任选有碱存在,
在钯存在下催化氢化后得到式(I)培哚普利,如果需要的话,将其转化为可药用盐如叔丁胺盐。
当式(IIa)化合物用作原料时,催化氢化优选在低于10bar的氢气压力下进行。
当式(IIb)化合物用作原料时,催化氢化优选在10至35bar的氢气压力下进行。
下述实施例解释说明本发明。
实施例1:(2S,3aS,7aS)-1-{(2S)-2-[(1S)-1-(乙氧羰基)-丁基氨基]-丙酰基}-八
氢-1H-吲哚-2-甲酸苄基酯:
将200g(2S,3aS,7aS)-八氢吲哚-2-甲酸苄基酯对甲苯磺酸盐、65ml三乙胺和1升乙酸乙酯加入搅拌的反应器中,于环境温度搅拌10分钟后,加入100g N-[(S)-乙氧羰基-1-丁基]-(S)-丙氨酸和175g O-(苯并三唑-1-基)-1,1,3,3-双(四亚甲基)脲六氟磷酸盐。然后将不均一混合物于30℃加热3小时,同时良好搅拌,然后冷却至0℃,过滤。然后洗涤滤液,随后蒸发至干,得到预期产物。
实施例2:(2S,3aS,7aS)-1-{(2S)-2-[(1S)-1-(乙氧羰基)-丁基氨基]-丙酰基-八氢-IH-吲哚-2-甲酸:
将前一步骤所得的残余物(200g)溶于20ml甲基环己烷中,转移至氢化器中;然后加入26g混悬于80ml甲基环己烷中的5%披钯炭,然后加入640ml水。然后将混合物于15至30℃和0.5bar压力下氢化,直至理论量的氢气被吸收。滤除催化剂后,将滤液的水相用甲基环己烷洗涤,然后冷冻干燥,得到预期产物,产率94%。
实施例3:(2S,3aS,7aS)-1-{(2S)-2-[(1S)-1-(乙氧羰基)-丁基氨基]-丙酰基}-八氢-1H-吲哚-2-甲酸叔丁胺盐:
将前一步骤所得的冷冻干燥物(200g)溶于2.8升乙酸乙酯中,然后加入44g叔丁胺和400ml乙酸乙酯。然后将所得混悬液回流至完全溶解;然后将所得溶液趁热过滤,搅拌冷却至15-20℃。然后过滤所得沉淀,用乙酸乙酯再次制成糊状,干燥,然后研磨,得到预期产物,产率95%。
Claims (6)
1.工业合成式(I)培哚普利及其可药用盐的方法,
其特征在于,使式(IIa)或(IIb)的苄基酯或者式(IIa)或(IIb)的酯与无机酸或有机酸的加成盐
与式(III)化合物
在偶联剂的存在下反应,所述的偶联剂选自下述试剂和试剂对:
(1,3-二甲基氨基丙基)-3-乙基-碳二亚胺盐酸盐,
(1,3-二甲基氨基丙基)-3-乙基-碳二亚胺盐酸盐/1-羟基苯并三唑,
(1,3-二甲基氨基丙基)-3-乙基-碳二亚胺盐酸盐/1-羟基-7-氮杂苯并三唑,
(1,3-二甲基氨基丙基)-3-乙基-碳二亚胺盐酸盐/N-羟基琥珀酰亚胺,
(1,3-二甲基氨基丙基)-3-乙基-碳二亚胺盐酸盐/3-羟基-3,4-二氢-4-氧代-1,2,3-苯并三嗪,
(1,3-二甲基氨基丙基)-3-乙基-碳二亚胺盐酸盐/N-羟基苯邻二甲酰亚胺,二环己基碳二亚胺/1-羟基-7-氮杂苯并三唑,
二环己基碳二亚胺/N-羟基琥珀酰亚胺,
二环己基碳二亚胺/3-羟基-3,4-二氢-4-氧代-1,2,3-苯并三嗪,
二环己基碳二亚胺/N-羟基苯邻二甲酰亚胺,
O-(苯并三唑-1-基)-1,1,3,3-四甲基脲六氟磷酸盐,
O-(7-氮杂苯并三唑-1-基)-1,1,3,3-四甲基脲六氟磷酸盐,
O-(苯并三唑-1-基)-1,1,3,3-四甲基脲四氟硼酸盐,
苯并三唑-1-基-氧基三吡咯烷子基磷六氟磷酸盐,
苯并三唑-1-基-氧基-三(二甲基氨基)磷六氟磷酸盐,
O-(苯并三唑-1-基)-1,1,3,3-双(四亚甲基)脲六氟磷酸盐,
O-(苯并三唑-1-基)-1,1,3,3-双(五亚甲基)脲六氟磷酸盐,
氯代-三吡咯烷子基磷六氟磷酸盐,
氯代-1,1,3,3-双(四亚甲基)甲脒六氟磷酸盐,
氯代-1,1,3,3-双(五亚甲基)甲脒六氟磷酸盐,
N-乙氧羰基-2-乙氧基-1,2-二氢喹啉,
O-[(乙氧羰基)-氰基亚甲基氨基]-1,1,3,3-四甲基脲四氟硼酸盐,
O-(3,4-二氢-4-氧代-1,2,3-苯并三嗪-3-基)-1,1,3,3-四甲基脲四氟硼酸盐,
O-(3,4-二氢-4-氧代-1,2,3-苯并三嗪-3-基)-1,1,3,3-四甲基脲四氟硼酸盐/1-羟基苯并三唑,
O-(3,4-二氢-4-氧代-1,2,3-苯并三嗪-3-基)-1,1,3,3-四甲基脲四氟硼酸盐/N-甲基吗啉,
O-(3,4-二氢-4-氧代-1,2,3-苯并三嗪-3-基)-1,1,3,3-四甲基脲四氟硼酸盐/三甲基吡啶,
O-(1,2-二氢-2-氧代-1-吡啶基)-1,1,3,3-四甲基脲四氟硼酸盐,
O-(1,2-二氢-2-氧代-1-吡啶基)-1,1,3,3-四甲基脲四氟硼酸盐/1-羟基-苯并三唑,
O-(1,2-二氢-2-氧代-1-吡啶基)-1,1,3,3-双(四亚甲基)脲六氟磷酸盐,
O-(1,2-二氢-2-氧代-1-吡啶基)-1,1,3,3-双(四亚甲基)脲六氟磷酸盐/1-羟基-苯并三唑,
O-(N-琥珀酰亚氨基)-1,1,3,3-四甲基脲四氟硼酸盐,
O-(N-琥珀酰亚氨基)-1,1,3,3-双(四亚甲基)脲四氟硼酸盐,
O-(N-琥珀酰亚氨基)-1,1,3,3-双(四亚甲基)脲四氟硼酸盐/1-羟基苯并三唑,
O-(5-降冰片烯-2,3-二甲酰亚氨基)-1,1,3,3-四甲基脲四氟硼酸盐,
丙烷磷酸酐,
N-羟基-5-降冰片烯-2,3-二甲酸酰亚胺,和
N-羟基-1,2-二氢-2-氧代-吡啶,
任选有碱存在,
在钯存在下催化氢化后得到式(I)培哚普利,如果需要的话,将其转化为可药用盐。
2.权利要求1的方法,用于合成叔丁胺盐形式的培哚普利。
3.权利要求1的方法,其特征在于使用式(IIa)化合物作为原料。
4.权利要求1的方法,其特征在于使用式(IIb)化合物作为原料。
5.权利要求3的方法,其特征在于氢化反应在低于10bar氢气压力下进行。
6.权利要求4的方法,其特征在于氢化反应在10至35bar氢气压力下进行。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03293084A EP1420029B9 (fr) | 2003-12-10 | 2003-12-10 | Procédé de synthèse du perindopril et ses sels pharmaceutiquement acceptables |
EP03293084.4 | 2003-12-10 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1890258A true CN1890258A (zh) | 2007-01-03 |
CN100453552C CN100453552C (zh) | 2009-01-21 |
Family
ID=32116381
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004800363546A Expired - Fee Related CN100453552C (zh) | 2003-12-10 | 2004-12-09 | 合成培哚普利及其可药用盐的方法 |
Country Status (27)
Country | Link |
---|---|
US (1) | US7279583B2 (zh) |
EP (1) | EP1420029B9 (zh) |
JP (1) | JP4377413B2 (zh) |
KR (1) | KR100825537B1 (zh) |
CN (1) | CN100453552C (zh) |
AR (1) | AR047327A1 (zh) |
AT (1) | ATE386745T1 (zh) |
AU (1) | AU2004312185B2 (zh) |
BR (1) | BRPI0417423B1 (zh) |
CA (1) | CA2548405C (zh) |
CY (1) | CY1108238T1 (zh) |
DE (1) | DE60319196T2 (zh) |
DK (1) | DK1420029T3 (zh) |
EA (1) | EA012034B1 (zh) |
ES (1) | ES2300555T3 (zh) |
GE (1) | GEP20084370B (zh) |
HK (1) | HK1095839A1 (zh) |
MA (1) | MA28222A1 (zh) |
MY (1) | MY139289A (zh) |
NO (1) | NO20063012L (zh) |
NZ (1) | NZ547550A (zh) |
PL (1) | PL211485B1 (zh) |
PT (1) | PT1420029E (zh) |
SI (1) | SI1420029T1 (zh) |
UA (1) | UA84898C2 (zh) |
WO (1) | WO2005066198A1 (zh) |
ZA (1) | ZA200604369B (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2413128A (en) * | 2004-04-13 | 2005-10-19 | Neopharma Ltd | Process for the preparation of perindopril |
PL1679072T3 (pl) * | 2005-01-06 | 2009-03-31 | Ipca Laboratories Ltd | Sposób syntezy pochodnych kwasu (2S, 3aS, 7aS)-1-(S)-alanylo- oktahydro-1H-indolo-2-karboksylowego i zastosowanie w syntezie perindoprilu |
WO2006131828A1 (en) * | 2005-06-08 | 2006-12-14 | Aurobindo Pharma Limited | A process for the preparation of perindopril |
US8686161B2 (en) * | 2008-06-24 | 2014-04-01 | Mylan Laboratories Limited | Polymorphic forms of perindopril (L)-arginine and process for the preparation thereof |
WO2016178591A2 (en) | 2015-05-05 | 2016-11-10 | Gene Predit, Sa | Genetic markers and treatment of male obesity |
FR3050380B1 (fr) | 2016-04-20 | 2020-07-10 | Les Laboratoires Servier | Composition pharmaceutique comprenant un betabloquant, un inhibiteur de l'enzyme de conversion et un antihypertenseur ou un ains. |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2807431B1 (fr) * | 2000-04-06 | 2002-07-19 | Adir | Nouveau procede de synthese du perindopril et de ses sels pharmaceutiquement acceptables |
-
2003
- 2003-12-10 EP EP03293084A patent/EP1420029B9/fr not_active Expired - Lifetime
- 2003-12-10 ES ES03293084T patent/ES2300555T3/es not_active Expired - Lifetime
- 2003-12-10 DK DK03293084T patent/DK1420029T3/da active
- 2003-12-10 AT AT03293084T patent/ATE386745T1/de active
- 2003-12-10 PT PT03293084T patent/PT1420029E/pt unknown
- 2003-12-10 DE DE60319196T patent/DE60319196T2/de not_active Expired - Lifetime
- 2003-12-10 SI SI200331193T patent/SI1420029T1/sl unknown
-
2004
- 2004-09-12 UA UAA200607608A patent/UA84898C2/uk unknown
- 2004-12-09 JP JP2006543583A patent/JP4377413B2/ja not_active Expired - Fee Related
- 2004-12-09 NZ NZ547550A patent/NZ547550A/en not_active IP Right Cessation
- 2004-12-09 ZA ZA200604369A patent/ZA200604369B/en unknown
- 2004-12-09 US US10/582,283 patent/US7279583B2/en not_active Expired - Fee Related
- 2004-12-09 PL PL380410A patent/PL211485B1/pl unknown
- 2004-12-09 CN CNB2004800363546A patent/CN100453552C/zh not_active Expired - Fee Related
- 2004-12-09 GE GEAP20049501A patent/GEP20084370B/en unknown
- 2004-12-09 AU AU2004312185A patent/AU2004312185B2/en not_active Ceased
- 2004-12-09 CA CA2548405A patent/CA2548405C/fr not_active Expired - Fee Related
- 2004-12-09 WO PCT/FR2004/003166 patent/WO2005066198A1/fr active Application Filing
- 2004-12-09 EA EA200601086A patent/EA012034B1/ru not_active IP Right Cessation
- 2004-12-09 BR BRPI0417423A patent/BRPI0417423B1/pt not_active IP Right Cessation
- 2004-12-09 MY MYPI20045097A patent/MY139289A/en unknown
- 2004-12-09 KR KR1020067013586A patent/KR100825537B1/ko not_active IP Right Cessation
- 2004-12-10 AR ARP040104613A patent/AR047327A1/es not_active Application Discontinuation
-
2006
- 2006-06-07 MA MA29083A patent/MA28222A1/fr unknown
- 2006-06-28 NO NO20063012A patent/NO20063012L/no not_active Application Discontinuation
-
2007
- 2007-03-20 HK HK07102976.7A patent/HK1095839A1/xx not_active IP Right Cessation
-
2008
- 2008-05-16 CY CY20081100813T patent/CY1108238T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1296355C (zh) | 合成培哚普利及其药学上可接受的盐的方法 | |
CN1529694A (zh) | 一种利用2,5-二氧代-噁唑烷中间体化合物制备哌道普利、其类似物及其盐的方法 | |
CN1890258A (zh) | 合成培哚普利及其可药用盐的方法 | |
CN1533398A (zh) | 合成(2S,3aS,7aS)-1-[(S)-丙氨酰基]-八氢-1H-吲哚-2-甲酸衍生物的新方法及其在合成哌林多普利中的用途 | |
CN1882607A (zh) | 合成培哚普利及其可药用盐的新方法 | |
CN1802384B (zh) | 培哚普利及其可药用盐的新合成方法 | |
CN1805972A (zh) | 培哚普利及其可药用盐的新合成方法 | |
CN1839147A (zh) | 合成培哚普利及其药学上可接受盐的新方法 | |
CN1835965A (zh) | 合成培哚普利及其药学可接受盐的新方法 | |
CN100383160C (zh) | 合成培哚普利及其药学上可接受盐的新方法 | |
CN1890259A (zh) | 合成(2s,3as,7as)-1-[(s)-1-丙氨酰基]-八氢-1h-吲哚-2-羧酸衍生物的方法及其用于合成培哚普利的用途 | |
CN1753907A (zh) | (2S,3aS,7aS)-1-[(S)-丙氨酰]-八氢-1H-吲哚-2-甲酸衍生物的新合成方法及其在合成培哚普利中的应用 | |
CN1826351A (zh) | 合成培哚普利及其药学可接受盐的新方法 | |
EP1628956A1 (en) | A process for the preparation of compounds having an ace inhibitory action | |
CN1753906A (zh) | 培哚普利和其可药用盐的新合成方法 | |
ZA200600479B (en) | Novel method for the synthesis of perindopril and the pharmaceutically acceptable salts thereof | |
TW202302620A (zh) | 胺基酸或肽之製造方法、保護基形成用試藥及化合物 | |
EP2906536A1 (en) | An improved process for preparation of perindopril intermediate | |
MXPA06006563A (en) | Method for the synthesis of derivatives of (2s, 3as, 7as)-1-[(s)-alanyl]-octahydro-1h |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1095839 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1095839 Country of ref document: HK |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090121 Termination date: 20181209 |